Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease

被引：0
|
作者：
Hughes, Derralynn [1 ]
Gonzalez, Derlis [2 ]
Maegawa, Gustavo [3 ]
Bernat, John [4 ]
Holida, Myrl [4 ]
Giraldo, Pilar [5 ]
Atta, Mohamed [6 ]
Chertkoff, Raul [7 ]
Alon, Sari [7 ]
Almon, Einat B. [7 ]
Rocco, Rossana [8 ]
Goker-Alpan, Ozlem [9 ]
机构：
[1] UCL, London, England
[2] Inst Privado Hematol & Invest Clin, Asuncion, Paraguay
[3] Univ Florida, Gainesville, FL USA
[4] Univ Iowa Hlth Care, Iowa City, IA USA
[5] Hosp Dia Quiron, Zaragoza, Spain
[6] Johns Hopkins Sch Med, Baltimore, MD USA
[7] Protalix Biotherapeut, Carmiel, Israel
[8] Chiesi Farmaceut SpA, Parma, Italy
[9] Lysosomal Disorders Res & Treatment Unit, Fairfax, VA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2022年 / 135卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2021.11.143
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
128
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [1] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
    Gonzalez, Derlis
    Maegawa, Gustavo
    Bernat, John
    Holida, Myrl
    Giraldo, Pilar
    Atta, Mohamed
    Chertkoff, Raul
    Alon, Sari
    Almon, Einat
    Rocco, Rossana
    Goker-Alpan, Ozlem
    GENETICS IN MEDICINE, 2022, 24 (03) : S91 - S91
  • [2] Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease
    Hughes, Derralynn
    Gonzalez, Derlis
    Maegawa, Gustavo
    Bernat, John A.
    Holida, Myrl
    Giraldo, Pilar
    Atta, Mohamed G.
    Chertkoff, Raul
    Alon, Sari
    Almon, Einat Brill
    Rocco, Rossana
    Goker-Alpan, Ozlem
    GENETICS IN MEDICINE, 2023, 25 (12)
  • [3] Long-term efficacy and safety of agalsidase alfa in women with Fabry disease
    Whybra, C.
    Kampmann, C.
    Miebach, E.
    Gal, A.
    Baron, K.
    Beck, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2008, 31 : 107 - 107
  • [4] Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Twoyear interim results from the ongoing phase 3 BRIGHT51 openlabel extension study
    Bernat, John
    Holida, Myrl D.
    Longo, Nicola
    Goker-Alpan, Ozlem
    Wallace, Eric
    Deegan, Patrick B.
    Tondel, Camilla
    Eyskens, Francois J.
    Feldt-Rasmussen, Ulla
    Hughes, Derralynn
    Pisani, Antonio
    Rocco, Rossana
    Almon, Einat Brill
    Alon, Sari
    Chertkoff, Raul
    Warnock, David G.
    Waldek, Stephen
    Wilcox, William R.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 16 - 16
  • [5] Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan
    Arakawa, Makoto
    Ikeda, Yoshinori
    Otaka, Hiromichi
    Iwashiro, Sanghun
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2024, 40
  • [6] Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease
    Lenders, Malte
    Menke, Elise Raphaela
    Rudnicki, Michael
    Cybulla, Markus
    Brand, Eva
    BIODRUGS, 2025, 39 (01) : 153 - 165
  • [7] A SUBGROUP ANALYSIS OF FEMALE PATIENTS IN A PHASE 3 OPEN-LABEL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PEGUNIGALSIDASE ALFA IN PATIENTS WITH FABRY DISEASE PREVIOUSLY TREATED WITH AGALSIDASE ALFA
    Hughes, Derralynn
    Dostalova, Gabriela
    Nicholls, Kathy
    West, Michael
    Tandel, Camilla
    Jovanovic, Ana
    Castellano, Pilar Giraldo
    Vujkovac, Bojan
    Geberhiwot, Tarekegn
    Almon, Einat
    Alon, Sari
    Szlaifer, Mali
    Chertkoff, Raul
    Linhart, Ales
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [8] Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study
    Kivitz A.
    Wallace T.
    Olech E.
    Borofsky M.
    Devenport J.
    Pei J.
    Michalska M.
    Rheumatology and Therapy, 2016, 3 (2) : 291 - 304
  • [9] Pegunigalsidase alfa, a novel PEGylated ERT for Fabry disease: Two-year safety and efficacy follow up
    Hughes, Derralynn
    Giraldo, Pilar
    Holida, Myrl
    Goker-Alpan, Ozlem
    Maegawa, Gustavo
    Schiffmann, Raphael
    Alon, Sari
    Filipovich, Margarita
    Szlaifer, Mali
    Brill-Almon, Einat
    Chertkoff, Raul
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S67 - S68
  • [10] Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
    Aleš Linhart
    Gabriela Dostálová
    Kathy Nicholls
    Michael L. West
    Camilla Tøndel
    Ana Jovanovic
    Pilar Giraldo
    Bojan Vujkovac
    Tarekegn Geberhiwot
    Einat Brill-Almon
    Sari Alon
    Raul Chertkoff
    Rossana Rocco
    Derralynn Hughes
    Orphanet Journal of Rare Diseases, 18
12345